(Cefpodoxime 200 mg + Potassium Clavulanate 125 mg)
Enhanced Broad-Spectrum Antibiotic for Resistant Bacterial Infections
VARPOD CV combines Cefpodoxime, a third-generation cephalosporin antibiotic, with
Potassium Clavulanate, a potent β-lactamase inhibitor. This synergistic combination enhances
the effectiveness of Cefpodoxime, allowing it to overcome bacterial resistance caused by
β-lactamase-producing organisms, thus offering a more comprehensive solution for various
bacterial infections.
Key Benefits:
● Broad-Spectrum Efficacy: Targets a wide range of both gram-positive and gram-negative
bacteria
● Overcomes Antibiotic Resistance: Potassium Clavulanate protects Cefpodoxime from
β-lactamase degradation, ensuring optimal performance
● Effective Against Resistant Strains: Useful in treating infections caused by resistant
pathogens
● Well-Tolerated: Proven to be well-accepted by patients with minimal side effects
● Convenient Dosage: Simple once or twice-daily dosing for patient compliance
Indications:
● Respiratory Tract Infections (e.g., pneumonia, bronchitis)
● Urinary Tract Infections (e.g., cystitis, pyelonephritis)
● Skin and Soft Tissue Infections
● Ear Infections (e.g., otitis media)
● Sinusitis
● Gonorrhea and other sexually transmitted infections